Preventive effect of piperonyl butoxide on cyclophosphamide-induced teratogenesis in rats

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 86, Issue 5, 2009, Pages 402-408

  Park, Dongsun ^a   Kim, Sunghyun ^a   Kang, Hyomin ^a   Oh, Jiyoung ^a   Ja, Young Jang ^a   Shin, Sunhee ^a   Tae, Kyun Kim ^a   Young, Jin Choi ^a   Sun, Hee Lee ^a   Kim, Ki Yon ^b   Seong, Soo Joo ^a   Kim, Yun Bae ^a,b  

^a Chungbuk National University   (South Korea)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cyclophosphamide; Cytochrome P 450 type 2B (CYP2B); Fetal defects; Piperonyl butoxide (PBO)

Indexed keywords

ACROLEIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B; MESSENGER RNA; PHOSPHORAMIDE MUSTARD; PIPERONYL BUTOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CESAREAN SECTION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FETUS DEVELOPMENT; GESTATION PERIOD; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; TERATOGENESIS; WEIGHT REDUCTION;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, ORAL; ANIMALS; BONE DEVELOPMENT; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B1; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; FETAL WEIGHT; GENE EXPRESSION REGULATION, DEVELOPMENTAL; LIVER; MALE; PESTICIDE SYNERGISTS; PIPERONYL BUTOXIDE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TERATOGENS;

CEPHALOCHORDATA; RATTUS;

EID: 70350732829     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20210     Document Type: Article

References (42)

1. Alarcon RA. 1976. Studies on the in vivo formation of acrolein: 3-hydroxypropyl-mercapturic acid as an index of cyclophosphamide (NSC-26271) activation. Cancer Treat Rep 60:327-335.
2. Ashby R, Davis L, Dewhurst BB, Espinal R, Penn RN, Upshall DG. 1976. Aspects of the teratology of cyclophosphamide (NSC-26271). Cancer Treat Rep 60:477-482.
3. Bailey MM, Sawyer RD, Behling JE, Boohaker JG, Hicks JG, O'Donnell MA, Stringer KR, Rasco JF, Hood RD. 2005. Prior exposure to indole-3-carbinol decreases the incidence of specific cyclophosphamide- induced developmental defects in mice. Birth Defects Res B 74:261-267.
4. Bryant PL, Schmid JE, Fenton SE, Buckalew AR, Abbott BD. 2001. Teratogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the expression of EGF and/or TGF-a. Toxicol Sci 62:103-114.
5. Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT. 1994. Cytochrome p450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923-936. (Pubitemid 24285170)
6. Chahoud I, Kuriyama SN, Paumgartten FJR. 2002. Maternal protein-and-energy restriction reduces the developmental toxicity of cyclophosphamide and hydroxyuria in rats. Toxicology 179:137-149. (Pubitemid 35245470)
7. Cohen JL, Jao JY. 1970. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J Pharmacol Exp Ther 174:206-210.
8. Cox PJ. 1979. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem Pharmacol 28:2045-2049.
9. Dawson AB. 1926. A note on the staining of the skeleton of cleared specimens with Alizarin red S. Stain Technol 1:123-124.
10. Fantel GE, Greenaway JC, Juchau MR, Shepard TH. 1979. Teratogenic bioactivation of cyclophosphamide in vitro. Life Sci 25:67-72.
11. Farnham AW. 1998. The mode of action of piperonyl butoxide with reference to studying pesticide resistance. In: Jones DG, editor. Piperonyl butoxide: The insecticide synergist. London: Academic Press. p 199-214.
12. Gibson JE, Becker BA. 1968. The teratogenicity of cyclophosphamide in mice. Cancer Res 28:475-480.
13. Gomes-Carneiro MR, De-Oliveira ACAX, De-Carvalho RR, Araujo IB, Souza CAM, Kuriyama SN, Paumgartten FJR. 2003. Inhibition of cyclophophamide-induced teratogenesis by β-ionone. Toxicol Lett 138:205-213.
14. Hales BF. 1981. Modification of the teratogenicity and mutagenicity of cyclophosphamide with thiol compounds. Teratology 23:373-381.
15. Hales BF. 1989. Effects of phosphoramide mustard and acrolein, cytotoxic metabolites of cyclophosphamide, on mouse limb development in vitro. Teratology 40:11-20.
16. Han S-Y, Shin J-H, Kwon SC, Kang MO, LEE YM, Kim PG, Yang M, Park KL, Jang SJ. 1995. Effects of enzyme inducers and glutathione on the embryotoxicity of cyclophosphamide in cultured rat embryos. Korean J Toxicol 11:31-36.
17. Hodgson E, Levi PE. 1998. Interactions of piperonyl butoxide with cytochrome P450. In: Jones DG, editor. Piperonyl butoxide: the insecticide synergist. London: Academic Press. p 41-54.
18. Kang H-G, Lee C-H, Lee K-C, Lee J-E, Kim H-J, Choi E- K, Yun YW, Kim Y-B. 2003. Effects of butylated hydroxyanisole on glutathione S-transferases activity and cyclophosphamide-induced teratogenicity in rats. J Toxicol Pub Health 19:181-187.
19. Kim H-J, Lee J-E, Choi E-K, Kim Y-B. 2003. Effects of butylated hydroxyanisole on glutathione S-transferases activity and teratogenicity of cyclophosphamide in mice. Korean J Lab Anim Sci 19:120-125.
20. Lee YE, Byun SK, Shin S, Jang JY, Choi B, Park D, Jeon JH, Lim SH, Hwang S-Y, Kim Y-B. 2005. Effect of red ginseng extract on cyclophosphamide teratogenicity in rats. Lab Anim Res 21:255-261.
21. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
22. Manson JM, Kang YJ. 1989. The methods for assessing female reproductive and developmental toxicology. In: Hayes AW, editor. Principles and methods of toxicology. New York: Raven Press. p 311-359.
23. Marinello AJ, Bansal SK, Paul B, Koser PL, Love J, Struck RF, Gurtoo HL. 1984. Metabolism and binding of cyclophosphamide and its metabolite acrolein to rat hepatic microsomal cytochrome P-450. Cancer Res 44:4615-4621. (Pubitemid 14008786)
24. Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG. 2001. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Human Reprod 16:632-637. (Pubitemid 32293787)
25. Mirkes PE. 1985. Cyclophosphamide teratogenesis: a review. Teratogen Carcinogen Mutagen 5:75-88.
26. Mirkes PE, Fantel AG, Greenaway JC, Shepard TH. 1981. Teratogenicity of cyclophosphamide metabolites: phosphoramide mustard, acrolein and 4-ketocyclophosphamide in rat embryos cultured in vitro. Toxicol Appl Pharmacol 58:322-330.
27. Neubert D, Barrach H-J. 1977. Organotropic effects and dose response relationship in teratology. In: Neubert D, editor. Methods in prenatal toxicology. Stuttgart: Georg Thieme Publishers. p 405-412.
28. Nishimura KA. 1974. Microdissection method for detecting thoracic visceral malformation in mouse and rat fetuses. Congenit Anom 14:23-40.
29. Park D, Jeon JH, Shin S, Joo SS, Kang D-H, Moon S-H, Jang M-J, Cho YM, Kim JW, Ji H-J, Ahn B, Oh K-W, Kim Y-B. 2009. Green tea extract increases cyclophosphamide-induced teratogenesis by modulating the expression of cytochrome P-450 mRNA. Reprod Toxicol 27:79-84.
30. Shah RM, Izadnegahdar MF, Henh BM, Young AV. 1996. In vivo/in vitro studies on the effects of cyclophosphamide on growth and differentiation of hamster palate. Anticancer Drugs 7:204-212.
31. Shin S, Jang JY, Lee YE, Byun SK, Choi B, Ryu JM, Park D, Jeon JH, Kim Y-B. 2006. Effect of Chunbo ginseng® extract on cyclophosphamide-induced teratogenicity in rats. Lab Anim Res 22:31-37.
32. Sieber SM, Adamson RH. 1975. Toxicity of antineoplastic agents in man, chromosome aberrations, antifertility effets, congenital malformations, and carcinogenic potential. Adv Cancer Res 22:57-155.
33. Slott VL, Hales BF. 1987. Enhancement of embryotoxicity of acrolein, but not phosphoramide mustard, by glutathione depletion in rat embryos in vitro. Biochem Pharmacol 36:2019-2025.
34. Slott VL, Hales BF. 1988. Role of the 4-hydroxy intermediate in the in vitro embryotoxicity of cyclophosphamide and dechlorocyclophosphamide. Toxicol Appl Pharmacol 92:170-178.
35. Ujhazy E, Balonova T, Durisova M, Gajdosik A, Jansak J, Molnarova A. 1993. Teratogenicity of cyclophosphamide in New Zealand white rabbits. Neoplasma 40:45-49. (Pubitemid 23138972)
36. Wexler P. 1998. Encyclopedia of toxicology, vol.I. New York: Academic Press. p 392-393.
37. Whitehouse MW, Beck FW, Droge MM, Struck RF. 1974. Lymphocyte deactivation by (potential immunosuppressant) alkylating metabolites of cyclophosphamide. Agents Actions 4:117-124.
38. Wilson JG. 1965. Methods for administering agents and detecting malformations in experimental animals. In:Wilson JG, editor. Teratology. Principles and techniques. Chicago: University of Chicago Press. p 262-277.
39. Yamamoto H. 1998. Effect of piperonyl butoxide or allopurinol on cyanide-induced lipid peroxidation in mouse brain. Toxicol Lett 94:167-173. (Pubitemid 28230996)
40. Yu LJ, Drewers P, Gustafsson K, Brain EGC, Hecht JED,Waxman DJ. 1999. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: Impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 288:928-937.
41. Zemlickis D, Lishner M, Erlich R, Koren G. 1993. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratogen Carcinogen Mutagen 13:139-143. (Pubitemid 23253372)
42. Zincke H, Woods JE. 1977. Donor pretreatment in cadaver renal transplantation. Surg Gynecol Obstet 145:183-188. (Pubitemid 8210130)